Evidence map›Paper›PMID 30135493›Full record

ArticleTranslational psychiatry2018

Lithium as a disease-modifying agent for prion diseases.

A Relaño-Ginés, S Lehmann, E Brillaud, M Belondrade, D Casanova, C Hamela, C Vincent, S Poupeau, J Sarniguet, T Alvarez and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. New Therapeutic Modalities in Prion Diseases.Sub-cellular biochemistry · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

A Relaño-GinésInstitut de Médecine Régénératrice et de Biothérapie (I.M.R.B.), Physiopathologie, diagnostic et thérapie cellulaire des affections neurodégénératives-Institut National de la Santé et de la Recherche Médicale Université de Montpellier U1183 Centre Hospitalo, Universitaire de Montpellier, Montpellier, France. aroa.relano-gines@umontpellier.fr.
S LehmannInstitut de Médecine Régénératrice et de Biothérapie (I.M.R.B.), Physiopathologie, diagnostic et thérapie cellulaire des affections neurodégénératives-Institut National de la Santé et de la Recherche Médicale Université de Montpellier U1183 Centre Hospitalo, Universitaire de Montpellier, Montpellier, France.
E BrillaudMedesis Pharma SA, Avenue du Golf, Baillargues, France.
M BelondradeInstitut de Génétique Humaine, Centre National de la Recherche Scientifique-UPR1142, Montpellier, France.
D CasanovaInstitut de Génétique Humaine, Centre National de la Recherche Scientifique-UPR1142, Montpellier, France.
C HamelaInstitut de Génétique Humaine, Centre National de la Recherche Scientifique-UPR1142, Montpellier, France.
C VincentMedesis Pharma SA, Avenue du Golf, Baillargues, France.
S PoupeauMedesis Pharma SA, Avenue du Golf, Baillargues, France.
J SarniguetMedesis Pharma SA, Avenue du Golf, Baillargues, France.
T AlvarezEtablissement Confiné d'Expérimentation BioCampus, Université Montpellier, Campus Triolet, Bâtiment 53, CECEMA, Montpellier, France.
J D ArnaudEtablissement Confiné d'Expérimentation BioCampus, Université Montpellier, Campus Triolet, Bâtiment 53, CECEMA, Montpellier, France.
J C MaurelMedesis Pharma SA, Avenue du Golf, Baillargues, France.
C CrozetInstitut de Médecine Régénératrice et de Biothérapie (I.M.R.B.), Physiopathologie, diagnostic et thérapie cellulaire des affections neurodégénératives-Institut National de la Santé et de la Recherche Médicale Université de Montpellier U1183 Centre Hospitalo, Universitaire de Montpellier, Montpellier, France. carole.crozet@inserm.fr.
Institut de Génétique Humaine · FRSasol (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prion diseases still remain incurable despite multiple efforts to develop a treatment. Therefore, it is important to find strategies to at least reduce the symptoms. Lithium has been considered as a neuroprotective agent for years, and the objective of this preclinical study was to evaluate the efficacy of lithium delivered as a water-in-oil microemulsion (Aonys

Indexed as

AnimalsBrainDisease Models, AnimalEmulsionsFemaleLithiumMiceMice, Inbred C57BLNeuroprotective AgentsPrion DiseasesPrionsEmulsionsLithiumNeuroprotective AgentsPrions

Identifiers

PMID30135493
PMCPMC6105724
OpenAlexW2888432269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.